NRX Pharmaceuticals, Inc.

Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.

NRXP | NDAQ

Overview

Corporate Details

ISIN(s):: US0894821034 (+2 more)
LEI:
Country:: United States of America
Address:: 1201 ORANGE STREET, 19801 WILMINGTON
Website:: https://www.nrxpharma.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system (CNS) disorders. The company is focused on addressing the high unmet medical need for treatments for severe bipolar depression and Post-Traumatic Stress Disorder (PTSD), particularly in patients with suicidal ideation. Its lead candidate, NRX-101, is the first investigational oral medication in FDA trials for suicidal bipolar depression and has received Fast Track and Breakthrough Therapy designations. The company's scientific platform is based on targeting the brain's NMDA receptor with a non-hallucinogenic, non-addictive approach. Its pipeline also includes KETAFREE™, a preservative-free ketamine product for suicidal depression.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NRX Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NRX Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for NRX Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Canopy Growth Corp Produces diverse cannabis products for medical and recreational markets globally.	United States of America	CGC
Cantourage Group SE A European platform producing and distributing medical cannabis products to pharmacies.	Germany	HIGH
CAPRICOR THERAPEUTICS, INC. Develops cell and exosome-based therapeutics for rare diseases like Duchenne muscular dystrophy.	United States of America	CAPR
CAREGEN CO.,LTD. Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.	South Korea	214370
Caribou Biosciences, Inc. Uses CRISPR genome editing to create off-the-shelf CAR-T cell therapies for cancer.	United States of America	CRBU
Carisma Therapeutics Inc. Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.	United States of America	CARM
Cartesian Therapeutics, Inc. Pioneering mRNA-engineered cell therapies to treat autoimmune diseases.	United States of America	RNAC
CASI Pharmaceuticals, Inc. Develops and commercializes drugs for oncology, transplant, and autoimmune disease.	United States of America	CASI
CASSAVA SCIENCES INC Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.	United States of America	SAVA
CATALYST PHARMACEUTICALS, INC. Advancing therapies for rare neuromuscular and neurological diseases like LEMS.	United States of America	CPRX